AMARILLO, Texas, Oct. 13 /PRNewswire/ -- Amarillo Biosciences, Inc.
(Nasdaq: AMAR) today announced Amarillo Biosciences is delisted from Nasdaq
because Nasdaq does not think the Company can "comply with all requirements
for continued inclusion on The Nasdaq SmallCap Market within a reasonable time
and sustain compliance with those requirements over the long term."
"We will appeal their decision within 15 days; the appeal process could
take until March or April. Whether we are traded on Nasdaq or over-the-counter
will not alter our focus on achieving FDA approval for low dose oral
interferon alpha," said Dr. Joseph Cummins, President and CEO.
Amarillo Biosciences, founded in 1984, is a world leader in the
development of oral interferon alpha as a treatment for a variety of
conditions including Sjogren's syndrome, fibromyalgia, opportunistic
infections in patients who are HIV positive, hepatitis B and hepatitis C.
Except for the historical information contained herein, the matters
discussed in this news release are forward-looking statements that involve
risks and uncertainties, including uncertainties related to product
development, uncertainties related to the need for regulatory and other
government approvals, dependence on proprietary technology, uncertainty of
market acceptance of oral interferon alpha or the company's other product
candidates and other risks detailed from time to time in the company's filings
with the Securities and Exchange Commission. In particular, see "Item 1.
Financial Business Risk Factors" of the company's Form 10-KSB for the year
ended Dec. 31, 1998."
SOURCE Amarillo Biosciences, Inc.
 back to top
Related links:
http://www.amacell.com
Company News On-Call:
http://www.prnewswire.com/comp/118055.html or fax,
800-758-5804, ext. 118055
CONTACT:
Kathleen L. Kelleher, COO and Vice President
Business Development of Amarillo Biosciences, Inc., 806-376-1741,
or email, ABI@AmarBio.com
|
